VivoSeq
Other

Abiraterone Acetate

0

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Abiraterone Acetate is an early-stage landscape with 0 programs across 5 companies. The most active players are Johnson & Johnson, Cougar Biotechnology, Inc., Aragon Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalC

Cougar Biotechnology, Inc.

0 programs

PreclinicalA

Aragon Pharmaceuticals, Inc.

0 programs

PreclinicalJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

PreclinicalA

Astex Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

28

clinical trials

Completed17 · 61%
Recruiting3 · 11%
Terminated2 · 7%
Withdrawn2 · 7%
Unknown status1 · 4%
Not yet recruiting1 · 4%
Other2 · 7%

Clinical Trials

Trial Activity

28 trials

Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
Recruiting·—·Phase 2·NCT06971211·40 enrolled
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Recruiting·EEmory University·Phase 3·NCT06650579·72 enrolled
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Recruiting·PPathos AI, Inc.·Phase 1/2·NCT06785636·252 enrolled
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Active, not recruiting·WWeill Medical College of Cornell University·Phase 1·NCT02913196·16 enrolled
Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC
Not yet recruiting·—·Phase 3·NCT06768255·400 enrolled
Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers
Completed·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT04863105·36 enrolled
Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT02230046·102 enrolled
A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers
Completed·CCougar Biotechnology, Inc.·Phase 1·NCT01362764·30 enrolled
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01588782·20 enrolled
A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01575587·51 enrolled
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Completed·AAragon Pharmaceuticals, Inc.·Phase 1·NCT01792687·6 enrolled
A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01640093·32 enrolled
A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01897389·32 enrolled
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT01314118·131 enrolled
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
Completed·GGU Research Network, LLC·Phase 3·NCT02887976·2 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)